Reinhard Dummer
莱因哈德·杜默
MD
Professor and Vice Chairman, Department of Dermatology; Head, Skin Cancer Unit皮肤科副主任教授，皮肤癌科主任
👥Biography 个人简介
Reinhard Dummer, MD is Professor and Vice Chairman of the Department of Dermatology at the University Hospital Zurich and Head of the Skin Cancer Unit, recognized internationally as a leading authority on targeted therapy for melanoma and the treatment of rare skin cancers. He was the principal investigator of the COLUMBUS trial—the pivotal phase III study of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) in BRAF V600-mutant advanced melanoma—which demonstrated a median progression-free survival of 14.9 months, the longest reported for any BRAF/MEK inhibitor combination at the time, leading to regulatory approval of this regimen in Europe and the United States. Dr. Dummer has also been a leading investigator in trials for cutaneous T-cell lymphoma, Merkel cell carcinoma, and other rare skin malignancies, and has contributed extensively to European melanoma treatment guidelines through his roles with ESMO and the European Dermatology Forum.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
COLUMBUS Trial: Encorafenib + Binimetinib in BRAF-Mutant Melanoma
Principal investigator of the COLUMBUS phase III trial demonstrating that encorafenib plus binimetinib achieved a median PFS of 14.9 months—superior to vemurafenib alone (7.3 months)—in BRAF V600-mutant advanced melanoma, leading to FDA and EMA approval of this combination and establishing it as a preferred BRAF/MEK inhibitor regimen.
Cutaneous T-Cell Lymphoma (CTCL) Treatment Innovation
Led major European clinical trials in cutaneous T-cell lymphoma including studies of mogamulizumab, histone deacetylase inhibitors, and novel combination approaches, contributing to approved therapies for mycosis fungoides and Sézary syndrome and establishing Zurich as a leading center for rare skin cancer management.
Merkel Cell Carcinoma Immunotherapy Development
Contributed as a key European investigator to trials of avelumab and pembrolizumab in Merkel cell carcinoma, contributing evidence supporting the first immunotherapy approvals for this aggressive neuroendocrine skin tumor and advancing the understanding of Merkel cell polyomavirus-related immune evasion.
European Melanoma Treatment Guidelines and Drug Development Leadership
Serves on ESMO clinical practice guideline committees for melanoma, has chaired or co-chaired multiple EORTC melanoma working group initiatives, and has led or participated in early-phase trials of novel BRAF and MEK inhibitors, helping define the European drug development landscape for skin cancers.
Representative Works 代表性著作
Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS)
The Lancet Oncology (2018)
Phase III COLUMBUS trial part 2 confirming encorafenib plus binimetinib superiority over vemurafenib with median PFS of 14.9 months, leading to regulatory approval of this BRAF/MEK combination.
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
New England Journal of Medicine (2019)
BEACON-CRC trial demonstrating the triplet combination of encorafenib, binimetinib, and cetuximab improved OS in BRAF V600E-mutant colorectal cancer, extending encorafenib/binimetinib utility beyond melanoma.
Avelumab versus Physician's Choice Chemotherapy as Third-Line Treatment of Patients with Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200)
The Lancet Oncology (2018)
Phase III trial demonstrating superior OS with avelumab versus chemotherapy in third-line Merkel cell carcinoma, supporting avelumab approval in this disease.
Mogamulizumab versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC)
The Lancet Oncology (2018)
Phase III MAVORIC trial demonstrating superiority of mogamulizumab over vorinostat in relapsed/refractory mycosis fungoides and Sézary syndrome, leading to regulatory approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 莱因哈德·杜默 的研究动态
Follow Reinhard Dummer's research updates
留下邮箱，当我们发布与 Reinhard Dummer（University Hospital Zurich (UniversitätsSpital Zürich)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment